illumina®

You've always had what it takes. **Now you have what you need.**

TruSight™ Oncology Comprehensive

TruSight Oncology Comprehensive is the first US FDA–approved, distributable CGP IVD with pan-cancer CDx claims.

TruSight Oncology Comprehensive provides clinically actionable guidance

Gain comprehensive insights

- One test detects DNA and RNA variants across 500+ genes and TMB for multiple solid tumor types
- Growing pipeline of tumor profiling and CDx claims

Enable precision medicine

- Content includes biomarkers indicated in drug labels, guidelines, and clinical trials[1]
- Patients matched with targeted treatments may experience improved outcomes[2]

TruSight Oncology Comprehensive improves turnaround time to results and access to the data

Process samples in-house

- Obtain results in 4-5 days with a sample-to-answer workflow
- Keep samples and data local for better control

Democratize access

- Increase the role of the local pathologists in the patient care pathway
- Pathway to expanded reimbursement, including coverage under National Coverage Determination (NCD) 90.2[3,4]

CDx, comparison diagnostic; CGP, comprehensive genomic profiling; TMB, tumor mutational burden

TruSight Oncology Comprehensive is approved by the US FDA and streamlines implementation

Trust your results

- Thoroughly validated by Illumina
- Reviewed and approved by the US FDA

Verify vs validate and save resources

- Reduce complexity of test implementation
- Optimize time to go-live with an easier verification process
- Rely on world-class Illumina service and support



Easier test implementation with the US FDA–approved TruSight Oncology Comprehensive assay—Implementing an *in vitro* diagnostic (IVD) test requires performance verification per guidelines in 42 CFR 493.1253[5] which is less resource-intensive than the validation required for a laboratory-develped test (LDT).[6] Illustrative example. Not meant to provide a precise comparison of time and resources.

Make personalized medicine the standard of care in oncology treatment

TruSight Oncology Comprehensive

illumina®

1.800.809.4566 toll-free (US) | +1.858.202.4566 tel
techsupport@illumina.com | www.illumina.com

References

1. Analysis provided by Velsera based on the TruSight Oncology Comprehensive software knowledge base.
2. Zehir A, Benayed R, Shah RH, et al. *Nat Med.* 2017;23(6):703-713. doi:10.1038/nm.4333
3. CMS. National Coverage Determination 90. 2 https://www.cms.gov/medicare-coverage-database/view/ncd.aspx?NCDId=372. Accessed August 1, 2024.
4. Policy Reporter. Data pulled in 2023.
5. 42 CFR 493.1253 https://www.ecfr.gov/current/title-42/chapter-IV/subchapter-G/part-493/subpart-K/subject-group-ECFRc96daead380f6ed/section-493.1253
6. Budelier MM, Hubbard JA. *J Mass Spectrom Adv Clin Lab.* 2023;28:67-69. doi:10.1016/j.jmsacl.2023.02.008

M-AMR-01465 v1.0

For *In Vitro* Diagnostic Use Only. Not available in all countries or regions.